Nitinol carotid stent enters trials:
This article was originally published in Clinica
US endovascular device start-up EndoTex Interventional Systems plans to begin a 45-patient, Phase I study of its nitinol carotid stent now that it has FDA approval to begin enrolling patients. The Cupertino, California-based company's NexStent device has been implanted in patients in Argentina and Chile under investigational use with no complications. The company, which counts Guidant and US Surgical (now Tyco) among its investors, has been developing nitinol-based vascular products for four years. EndoTex also has an agreement to develop products for repairing aortic aneurysms and AV fistulas with US Surgical.